RxSight (RXST) EBITDA (2020 - 2026)

RxSight (RXST) has 7 years of EBITDA data on file, last reported at -$16.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 91.87% year-over-year to -$16.0 million; the trailing twelve-month figure through Mar 2026 stood at -$46.7 million (down 76.46% YoY), and the FY2025 full-year result was -$39.1 million, down 43.15% from the prior year.
• EBITDA for Q1 2026 stood at -$16.0 million, down from -$9.2 million in the prior quarter.
• Across five years, EBITDA topped out at -$5.7 million in Q3 2024 and bottomed at -$17.7 million in Q1 2022.
• The 5-year median for EBITDA is -$11.9 million (2025), against an average of -$11.6 million.
• The widest annual swing landed in 2022, when EBITDA slumped 159.84%; it then soared 55.7% in 2024.
• A 5-year view of EBITDA shows it stood at -$15.6 million in 2022, then surged by 41.4% to -$9.1 million in 2023, then surged by 31.01% to -$6.3 million in 2024, then sank by 45.56% to -$9.2 million in 2025, then slumped by 74.72% to -$16.0 million in 2026.
• The last three EBITDA figures came in at -$16.0 million (Q1 2026), -$9.2 million (Q4 2025), and -$9.6 million (Q3 2025), per Business Quant data.

Peer Comparison